Synairgen (GB:SNG) has released an update.
Synairgen plc has announced interim results for the first half of 2024, revealing progress in their Phase 2 trial preparations for SNG001, an inhaled antiviral treatment for mechanically ventilated patients. Despite a decrease in cash and deposit balances alongside a net loss, the company has reduced its R&D and administrative expenditures. Synairgen is gearing up for a significant Phase 2 trial and plans to raise additional funds to finance it, with an emphasis on addressing the high mortality rates in mechanically ventilated patients due to severe viral lung infections.
For further insights into GB:SNG stock, check out TipRanks’ Stock Analysis page.
